Holly Siegfried

Doctor of Osteopathic Medicine,  Massachusetts General Hospital 

Location: Africa

Consulting Services

Case Consulting Biostatistics

Areas Of Interest

Inert Gas Narcosis PMS-Desipramine Lutein Cells Codon Bias Microcycas Compounds, Ferric System, Argentaffin GAT3 Transporter Ferredoxin II Optic Disks Sperm, X-Bearing Apocytochrome b6 Disequilibrium, Linkage Gram Positive Bacterial Infections Surgeries, Video-Assisted Thoracic Human poliovirus 3 Statistical Data Interpretation Polymers, Propylene Peri Implant Fractures BEK Protein Tyrosine Kinase Cognition Therapy Kaolinite c-erbB-2 Genes Cerebral Microangiopathies Gs Stimulatory G Proteins Physical Performance Between Person Biological Variation Sphincter of Oddi Stenosis Pinealoma Bismethyl Suberimidate Piriform Sinus Bacterial O Antigen Vapor Lasers, Metal Case Studies, Management Microtubule Proteins Terminalia Puma lentivirus Equine Encephalomyelitis Virus Infections Cycle, Carbon

Professional Narrative

Dr. Holly Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Director Medicine, Harvard Med 2003
Senior Director, Harvard Med 1987

Education

Doctor of osteopathic medicine, Yale School of Medicine 1993
Doctor of osteopathic medicine, Weill Medical College 1988

Referees

Publications

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440-55. doi: 10.1016/j.cell.2014.09.014. Epub 2014 Sep 25. PMID: 25263330; PMCID: PMC4265475.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02